Abstract

LIMA-PEREZ, Mayté et al. Nimotuzumab combined with GEMOX chemotherapy regimen in patients with advanced pancreatic cancer. Vaccimonitor [online]. 2021, vol.30, n.3, pp. 133-144.  Epub Dec 01, 2021. ISSN 1025-0298.

A retrospective and observational study was carried out in patients with advanced pancreatic adenocarcinoma, treated with Nimotuzumab combined with a GEMOX chemotherapy scheme, in the Clinical Oncology Service at the Ameijeiras Hospital, between 2013 and 2019 (n =118), whose objective was to evaluate the response to the treatment and overall survival according to clinical, histopathological and treatment variables. The chi-square method was used for the association of variables. Overall survival was evaluated by the Kaplan Meier method and the Log-Rank and Breslow test for the comparison of the curves, with p <0.05. The disease control rate was 44.9. The median survival was 13.8 months (95% CI: 11.7-15.8). The statistically significant variables associated with greater response to treatment and survival were: no smoking habits; platelet-lymphocyte index below 200; T2-T3 primary tumors, predominantly located in the pancreatic head; no presence of metastases at diagnosis and greater than six doses of chemotherapy and Nimotuzumab. Patients classified as underweight and low serum albumin had worse survival (p <0.05). Second-line chemotherapy was performed in 42 patients and it was obtained SV of 17.4 months (95% CI: 13.5-21.4). Toxicities classified as grade 3-4 were reported in 27 patients (22.9%); the most frequently observed were: neuropathy (14.4%), neutropenia (10.2%) and thrombopenia (9.3%). Under clinical practice conditions, Nimotuzumab combined with GEMOX chemotherapy obtained optimal disease control and survival rates with a good safety profile.

Keywords : Nimotuzumab; pancreatic cancer; drug therapy; survival analysis.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )